NASDAQ · NOVN
Healthcare · Biotechnology
$0.09
Down-$0.03 (-24.84%)
Updated Oct 7, 2026, 12:40 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NOVN
1M range · 0 trading sessions · Daily adjusted prices
NOVN does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NOVN.
Company
Market Activity
Research & News
NOVN research
Company profile and research snapshot.
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 1, 2023 | Oppenheimer | Perform | — |
| May 16, 2023 | Oppenheimer | Outperform | — |
| Mar 31, 2023 | Cantor Fitzgerald | Overweight | — |
| Aug 16, 2022 | HC Wainwright & Co. | Buy | — |
| Jul 19, 2022 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
globenewswire.com · Sep 29, 2025
Peanut allergy is a growing health concern, especially in children, with rising incidence and increased public awareness of its severity and risks. This
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NOVN.
No results
No recent SID articles mention NOVN.
